癌症患者血清可溶性肿瘤坏死因子受体Ⅰ的测定及分析  

Determination and analysis of serum soluble tumor necrosis factor receptor Ⅰ (sTNFRⅠ) levels in cancer patients

作　　者：白岚[1] 姜云飞[1] 袁爱力[1] 黄玫 牛杰志 赖卓胜[1] 

机构地区：[1]南方医院消化科,广州510515 [2]广州空军医院肿瘤科

出　　处：《实用肿瘤杂志》1997年第1期9-11,共3页Journal of Practical Oncology

基　　金：广东省自然科学基金

摘　　要：采用酶联免疫吸附法（ELISA）检测了177例癌症（其中食管瘤2例、胃癌12例、肠癌47例、肝癌71例、胆管癌1例、胰腺癌4例、肺癌26例、乳腺癌9例、卵巢癌2例、子宫癌2例、鼻咽癌1例）患言血清可溶性肿瘤坏死因子受体I（sTNFRI）水平。结果显示病人血清中sTNFRI浓度（12904±45．58U／ml）显著高于正常对照组（51．64±26.67U／ml）．P＜0．05，而在各种癌症患者中，肝癌病人的sTNFRI水平为最高（223.07±177．16U／ml）。其结果对了解肿瘤病人的异常免疫状态以及sTNFRI检测的临床价值具有重要意义。The study was undertaken to detect serum sTNFR I levels in 177 cancer patients (including 2 cases of esophagus cancer. 12 stomach, 1 bile duct, 4 pancreas. 47 colorectum, 71 liver, 26 lung. 9 breast, 2 ovary, 2 uterus and 1 pharyngeas) using sandwich enzyme-linked immune sorbent assay. The results showed that the sTNFR I levels were significantly higher in patients with carcinoma than those in healthy controls. Among all cancer patients, the patients with liver cancer had the highest serum sTNFR I concentration. The correlations between the serum sTNFR I levels and the staging of cancer patients, the other laboratory parameters were also analyzed and discussed. The data indicate that sTNFR I may serve as a marker for abnormal immune status and prognosis of the cancer patients.

关 键 词：肿瘤 癌 肿瘤坏死因子 STNFR 测定 ELISA 

分 类 号：R730.4[医药卫生—肿瘤]